التفاصيل البيبلوغرافية
| العنوان: |
Proposal for generating new beta cells in a muted immune environment for type 1 diabetes |
| المؤلفون: |
Levetan, Claresa, Pozzilli, Paolo, Jovanovic, Lois, Schatz, Desmond |
| المصدر: |
Diabetes/Metabolism Research and Reviews ; volume 29, issue 8, page 604-606 ; ISSN 1520-7552 1520-7560 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2013 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Background Over the past decade, many immune tolerance agents have shown promise in the non‐obese diabetic mouse model for prevention and reversal of type 1 diabetes but have not been successful in clinical trials among recently diagnosed type 1 patients. The trials from decades ago using Cyclosporine A in significantly lower dosages than used for organ transplantation and in similar dosages that have increased T regulatory cell populations in conditions such as atopic dermatitis, demonstrated very high initial insulin‐free remission rates when administered immediately after diagnosis. Over time, all newly diagnosed type 1 patients given Cyclosporine A required insulin. Human trials with immune tolerance agents suggest that in addition to an immune tolerance agent, a beta cell regeneration agent may also be necessary to induce long‐lasting remission among patients with recent onset type 1 diabetes. Methods A randomized, double‐blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton‐pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets. © 2013 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons, Ltd. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1002/dmrr.2435 |
| الإتاحة: |
https://doi.org/10.1002/dmrr.2435Test |
| حقوق: |
http://creativecommons.org/licenses/by-nc/3.0Test/ |
| رقم الانضمام: |
edsbas.B152E89F |
| قاعدة البيانات: |
BASE |
